SOLID ORAL FORMULATION OF A PYRROLIDINE SUBSTITUTED FLAVONE COMPOUND

The present invention relates to a pharmaceutical composition providing a self emulsifying drug delivery system (SEDDS) for oral administration, comprising a compound, (+) trans-2-(2-chloro-phenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1- methyl-pyrrolidin-3-yl)-chromen-4-one or a pharmaceutically accept...

Full description

Saved in:
Bibliographic Details
Main Authors VARTAK, MILIND, ENOSE, ARNO, APPAVOO, NERURKAR, MANEESH
Format Patent
LanguageEnglish
French
Published 18.09.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a pharmaceutical composition providing a self emulsifying drug delivery system (SEDDS) for oral administration, comprising a compound, (+) trans-2-(2-chloro-phenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1- methyl-pyrrolidin-3-yl)-chromen-4-one or a pharmaceutically acceptable salt thereof, along with one or more surfactant and a solubilizer. The present invention also relates to a process for preparation of said pharmaceutical composition and use of the pharmaceutical composition in the treatment of a disease or disorder selected from cancer, polycystic kidney disease, nephrological disorder, psoriasis, immunological disorder involving unwanted proliferation of leukocytes, restenosis, proliferative smooth muscle disorder, radiation induced mucositis, viral infection, mycotic infection or cardiovascular abnormality. La présente invention concerne une composition pharmaceutique constituant un système d'administration de médicament auto-émulsifiant (SEDDS) pour administration orale, comprenant un composé, (+)trans-2-(2-chloro-phényl)-5,7-dihydroxy-8-(2-hydroxyméthyl-1-méthyl-pyrrolidin-3-yl)-chromén-4-one ou un sel pharmaceutiquement acceptable de celui-ci, ainsi qu'un ou plusieurs tensioactifs et un solubilisant. La présente invention concerne en outre un procédé pour la préparation de ladite composition pharmaceutique et l'utilisation de la composition pharmaceutique dans le traitement d'une maladie ou un trouble choisi parmi le cancer, la maladie polykystique des reins, un trouble néphrologique, un psoriasis, un trouble immunologique impliquant une prolifération indésirable de leucocytes, une resténose, un trouble de prolifération de muscle lisse, une mucosite induite par rayonnement, une infection virale, une infection fongique ou une anomalie cardiovasculaire.
Bibliography:Application Number: WO2013IB52069